Effects of IP-751, ajulemic acid, on bladder overactivity induced by bladder irritation in rats. 2007

Shiro Hiragata, and Teruyuki Ogawa, and Yukio Hayashi, and Pradeep Tyagi, and Satoshi Seki, and Osamu Nishizawa, and Fernando de Miguel, and Michael B Chancellor, and Naoki Yoshimura
Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA.

OBJECTIVE Ajulemic acid (IP-751) is a synthetic analog of tetrahydrocannabinol, which is a major ingredient of the plant Cannabis. IP-751 reportedly shows potent anti-inflammatory activity and is a powerful analgesic agent. Thus, we examined whether IP-751 can suppress urinary frequency induced by nociceptive stimuli in the bladder. METHODS Continuous cystometry (infusion rate 0.04 mL/min) under urethane anesthesia was performed to evaluate the effect of intravenous injection of IP-751 with or without a cannabinoid-1 receptor antagonist (AM251) or a cannabinoid-2 receptor antagonist (AM630) on bladder function in normal rats and rats with urinary frequency induced by intravesical infusion with 0.25% acetic acid or cyclophosphamide (CYP) (150 mg/kg intraperitoneally, 48 hours before cystometrography). RESULTS When 10 mg/kg of IP-751 was injected in normal rats, the intercontraction interval (ICI) and pressure threshold increased. A 0.25% acetic acid infusion induced urinary frequency, as evidenced by a reduction in ICIs, which were suppressed by injection of IP-751 (10 mg/kg). Urinary frequency, indicated by significant ICI reductions, was also observed in the CYP-treated rats. Administration of IP-751 (10 mg/kg) significantly suppressed CYP-induced urinary frequency, as evidenced by the increase in the ICI. When AM251, but not AM630, was administered before IP-751, the IP-751-induced increases in the ICI and pressure threshold were prevented in all three groups. In addition, administration of AM251 alone decreased the ICIs in CYP-treated rats. CONCLUSIONS IP-751 can suppress normal bladder activity and urinary frequency induced by bladder nociceptive stimuli, probably by suppression of bladder afferent activity. These inhibitory effects of IP-751 are at least in part mediated by the cannabinoid-1 receptor.

UI MeSH Term Description Entries
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013759 Dronabinol A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound. THC,Tetrahydrocannabinol,delta(9)-THC,9-ene-Tetrahydrocannabinol,Marinol,Tetrahydrocannabinol, (6a-trans)-Isomer,Tetrahydrocannabinol, (6aR-cis)-Isomer,Tetrahydrocannabinol, (6aS-cis)-Isomer,Tetrahydrocannabinol, Trans-(+-)-Isomer,Tetrahydrocannabinol, Trans-Isomer,delta(1)-THC,delta(1)-Tetrahydrocannabinol,delta(9)-Tetrahydrocannabinol,9 ene Tetrahydrocannabinol,Tetrahydrocannabinol, Trans Isomer
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D053201 Urinary Bladder, Overactive Symptom of overactive detrusor muscle of the URINARY BLADDER that contracts with abnormally high frequency and urgency. Overactive bladder is characterized by the frequent feeling of needing to urinate during the day, during the night, or both. URINARY INCONTINENCE may or may not be present. Overactive Detrusor,Bladder, Overactive,Overactive Bladder,Overactive Detrusor Function,Overactive Urinary Bladder,Detrusor Function, Overactive,Detrusor, Overactive

Related Publications

Shiro Hiragata, and Teruyuki Ogawa, and Yukio Hayashi, and Pradeep Tyagi, and Satoshi Seki, and Osamu Nishizawa, and Fernando de Miguel, and Michael B Chancellor, and Naoki Yoshimura
June 2005, The AAPS journal,
Shiro Hiragata, and Teruyuki Ogawa, and Yukio Hayashi, and Pradeep Tyagi, and Satoshi Seki, and Osamu Nishizawa, and Fernando de Miguel, and Michael B Chancellor, and Naoki Yoshimura
July 2004, The European journal of neuroscience,
Shiro Hiragata, and Teruyuki Ogawa, and Yukio Hayashi, and Pradeep Tyagi, and Satoshi Seki, and Osamu Nishizawa, and Fernando de Miguel, and Michael B Chancellor, and Naoki Yoshimura
September 2016, International urogynecology journal,
Shiro Hiragata, and Teruyuki Ogawa, and Yukio Hayashi, and Pradeep Tyagi, and Satoshi Seki, and Osamu Nishizawa, and Fernando de Miguel, and Michael B Chancellor, and Naoki Yoshimura
March 2010, Urology,
Shiro Hiragata, and Teruyuki Ogawa, and Yukio Hayashi, and Pradeep Tyagi, and Satoshi Seki, and Osamu Nishizawa, and Fernando de Miguel, and Michael B Chancellor, and Naoki Yoshimura
July 2011, The Journal of urology,
Shiro Hiragata, and Teruyuki Ogawa, and Yukio Hayashi, and Pradeep Tyagi, and Satoshi Seki, and Osamu Nishizawa, and Fernando de Miguel, and Michael B Chancellor, and Naoki Yoshimura
August 2011, Urology,
Shiro Hiragata, and Teruyuki Ogawa, and Yukio Hayashi, and Pradeep Tyagi, and Satoshi Seki, and Osamu Nishizawa, and Fernando de Miguel, and Michael B Chancellor, and Naoki Yoshimura
June 2000, The Journal of pharmacology and experimental therapeutics,
Shiro Hiragata, and Teruyuki Ogawa, and Yukio Hayashi, and Pradeep Tyagi, and Satoshi Seki, and Osamu Nishizawa, and Fernando de Miguel, and Michael B Chancellor, and Naoki Yoshimura
October 1999, The Journal of urology,
Shiro Hiragata, and Teruyuki Ogawa, and Yukio Hayashi, and Pradeep Tyagi, and Satoshi Seki, and Osamu Nishizawa, and Fernando de Miguel, and Michael B Chancellor, and Naoki Yoshimura
December 2012, The Journal of urology,
Shiro Hiragata, and Teruyuki Ogawa, and Yukio Hayashi, and Pradeep Tyagi, and Satoshi Seki, and Osamu Nishizawa, and Fernando de Miguel, and Michael B Chancellor, and Naoki Yoshimura
February 1998, The Journal of urology,
Copied contents to your clipboard!